Area of research
Pulmonary and Respiratory Medicine · Emergency Medical Services
Research interest
Research interests include Medicine, Cystic fibrosis, Ivacaftor, Cystic fibrosis transmembrane conductance regulator, Internal medicine, and Food and drug administration.
First real-world study of fetal therapy with CFTR modulators in cystic fibrosis: Report from the MODUL-CF study
Sweat chloride and lung function responses to elexacaftor–tezacaftor–ivacaftor in people with cystic fibrosis with two versus one responsive CFTR variants: an analysis of two real-world observational studies
Standards for the care of people with cystic fibrosis (CF); recognising and addressing CF health issues
The expanded French compassionate programme for elexacaftor–tezacaftor–ivacaftor use in people with cystic fibrosis without a F508del CFTR variant: a real-world study
Multisystemic Effects of Elexacaftor–Tezacaftor–Ivacaftor in Adults with Cystic Fibrosis and Advanced Lung Disease
Gathering real-world compassionate data to expand eligibility for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with N1303K or other rare<i>CFTR</i>variants: a viewpoint
Theratyping cystic fibrosis patients to guide elexacaftor/tezacaftor/ivacaftor out-of-label prescription
The French Compassionate Program of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis with advanced lung disease and no F508del<i>CFTR</i>variant
Standards of care for CFTR variant-specific therapy (including modulators) for people with cystic fibrosis
Sustained effectiveness of elexacaftor-tezacaftor-ivacaftor in lung transplant candidates with cystic fibrosis
Factors associated with clinical progression to severe COVID-19 in people with cystic fibrosis: A global observational study
Cumulative Incidence and Risk Factors for Severe Coronavirus Disease 2019 in French People With Cystic Fibrosis
Rapid Improvement after Starting Elexacaftor–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and Advanced Pulmonary Disease
Using chest CT scan and unsupervised machine learning for predicting and evaluating response to lumacaftor-ivacaftor in people with cystic fibrosis
The global impact of SARS-CoV-2 in 181 people with cystic fibrosis
Lung immunoglobulin A immunity dysregulation in cystic fibrosis
Clinical response to lumacaftor-ivacaftor in patients with cystic fibrosis according to baseline lung function
Increased IgA Expression in Lung Lymphoid Follicles in Severe Chronic Obstructive Pulmonary Disease